HBP vs. MDNA, BCT, IPA, ONC, SCYB, COM, NVH, SVA, IGX, and TH
Should you be buying Helix BioPharma stock or one of its competitors? The main competitors of Helix BioPharma include Medicenna Therapeutics (MDNA), BriaCell Therapeutics (BCT), ImmunoPrecise Antibodies (IPA), Oncolytics Biotech (ONC), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), Sernova (SVA), IntelGenx Technologies (IGX), and Theratechnologies (TH). These companies are all part of the "biotechnology" industry.
Helix BioPharma (TSE:HBP) and Medicenna Therapeutics (TSE:MDNA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability.
Helix BioPharma's return on equity of 0.00% beat Medicenna Therapeutics' return on equity.
Medicenna Therapeutics received 22 more outperform votes than Helix BioPharma when rated by MarketBeat users. Likewise, 68.22% of users gave Medicenna Therapeutics an outperform vote while only 63.46% of users gave Helix BioPharma an outperform vote.
14.2% of Medicenna Therapeutics shares are owned by institutional investors. 20.5% of Helix BioPharma shares are owned by insiders. Comparatively, 22.1% of Medicenna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Helix BioPharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Medicenna Therapeutics had 1 more articles in the media than Helix BioPharma. MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for Helix BioPharma. Helix BioPharma's average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.
Helix BioPharma has a beta of -0.78, suggesting that its stock price is 178% less volatile than the S&P 500. Comparatively, Medicenna Therapeutics has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.
Summary
Medicenna Therapeutics beats Helix BioPharma on 7 of the 11 factors compared between the two stocks.
Get Helix BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for HBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Helix BioPharma Competitors List
Related Companies and Tools
